loading page

Role of PD-1/PD-L1 inhibitors in the treatment of recurrent/metastatic head and neck squamous cell carcinoma: a systematic review and meta-analysis
  • +1
  • gaofei Yin,
  • Wei Guo,
  • Hanyuan Duan,
  • zhigang Huang
gaofei Yin
Beijing Tongren Hospital Department of Otorhinolaryngology and Head and Neck Surgery
Author Profile
Wei Guo
Beijing Tongren Hospital Department of Otorhinolaryngology and Head and Neck Surgery
Author Profile
Hanyuan Duan
Beijing Tongren Hospital Department of Otorhinolaryngology and Head and Neck Surgery
Author Profile
zhigang Huang
Beijing Tongren Hospital Department of Otorhinolaryngology and Head and Neck Surgery
Author Profile

Abstract

Background: The use of immunotherapy to treat recurrent/metastatic squamous cell carcinoma of the head and neck has become a popular research topic in recent years, and many clinical trials have been carried out. Objectives: To systematically evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of recurrent/metastatic head and neck squamous cell carcinoma. Methods: We searched PubMed, Embase, Cochrane Library and other databases up to 1 November 2019 for publications reporting the use of PD-1/PD-L1 inhibitors in the treatment of squamous cell carcinoma of the head and neck. Revman 5.0 was used for combination analysis, and the overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and adverse events were determined. Results: Five articles were included. Compared with other treatment methods, this meta-analysis showed that treatment with PD-1/PD-L1 inhibitors can significantly improve OS (P < 0.0001), but there was no significant improvement in PFS or ORR. The risk of anaemia and nausea was significantly reduced by treatment with PD-1/PD-L1 inhibitors. Conclusions and Significance: Treatment with PD-1/PD-L1 inhibitors alone can improve the overall survival rate for recurrent/metastatic squamous cell carcinoma of the head and neck but there is no obvious advantage in other aspects and adverse events.

Peer review status:ACCEPTED

27 Apr 2020Submitted to Clinical Otolaryngology
29 Apr 2020Submission Checks Completed
29 Apr 2020Assigned to Editor
28 May 2020Reviewer(s) Assigned
23 Aug 2020Review(s) Completed, Editorial Evaluation Pending
30 Aug 2020Editorial Decision: Revise Minor
01 Sep 20201st Revision Received
12 Sep 2020Submission Checks Completed
12 Sep 2020Assigned to Editor
08 Nov 2020Reviewer(s) Assigned
28 Dec 2020Review(s) Completed, Editorial Evaluation Pending
03 Jan 2021Editorial Decision: Revise Major
10 Jan 20212nd Revision Received
14 Jan 2021Submission Checks Completed
14 Jan 2021Assigned to Editor
24 Feb 2021Reviewer(s) Assigned
13 Mar 2021Review(s) Completed, Editorial Evaluation Pending
14 Mar 2021Editorial Decision: Revise Minor
15 Mar 20213rd Revision Received
16 Mar 2021Submission Checks Completed
16 Mar 2021Assigned to Editor
21 Mar 2021Review(s) Completed, Editorial Evaluation Pending
21 Mar 2021Editorial Decision: Accept